The role of vildagliptin in the management of type 2 diabetes mellitus

Annals of Pharmacotherapy

Volumn 41, Issue 5, 2007, Pages 824-832

  Kleppinger, Erika L ^a,b   Helms, Kristen ^a  

^a AUBURN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

Dipeptidyl peptidase IV inhibitor; LAF237; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLIBENCLAMIDE; GLUCAGON; GLUCAGON DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; PIOGLITAZONE; PLACEBO; VILDAGLIPTIN;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; CONSTIPATION; COUGHING; DIABETIC PATIENT; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INFECTION; INSULIN BLOOD LEVEL; INSULIN RELEASE; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADAMANTANE; ADENOSINE DEAMINASE; ANIMALS; ANTIGENS, CD26; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; GLUCAGON-LIKE PEPTIDE 1; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; NITRILES; PYRROLIDINES;

EID: 34248590514     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H460     Document Type: Article

References (29)

1. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2005.
2. Package insert. Byetta (exenatide). San Diego, CA: Amylin Pharmaceuticals, Inc. April 2006. http://pi.lilly.com/us/byetta-pi.pdf (accessed 2006 Jul 31).
3. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
4. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:1963-72.
5. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007;30(suppl 1):S4-41.
6. McIntosh CHS, Demuth H, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 2005;128:159-65.
7. Meier JJ, Gallwitz B, Nauck MA. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs 2003;17:93-102.
8. Nielsen LL. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 2005;10:703-10.
9. Bloomgarden ZT. Gut-derived incretin hormones and new therapeutic approaches. Diabetes Care 2004;27:2554-9.
10. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 2004;47:4135-41.
11. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998;47:1663-70.
12. McIntyre JA, Castaner J. Vildagliptin. Drugs Future 2004;29:887-91.
13. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-89.
14. Ahren B, Landin-Olsson M, Jannson P, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84.
15. Brandt I, Joossens J, Chen X, et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1- yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem Pharmacol 2005;70:134-43.
16. He YL, Sabo R, Wang Y, Ligueros-Saylan M, Dole WP. The influence of hepatic impairment on the pharmacokinetics of vildagliptin (poster). Presented at: American Diabetes Association 66th Annual Scientific Sessions, Washington, DC, June 9-13, 2006.
17. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692-8.
18. Novartis Clinical Trial Results Database. Diabetes: vildagliptin. Study number LAF237A2203E1. www.novartisclinicaltrials.com/clinicaltrialrepository/ displayFile.do?trialResult=1890 (accessed 2006 Aug 10).
19. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423-8.
20. Dejager S, Lebeaut A, Couturier A, Schweizer A. Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (abstract). Presented at: American Diabetes Association 66th Annual Scientific Sessions, Washington, DC, June 10, 2006.
21. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care 2007;30:217-23.
22. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27: 2874-80.
23. Novartis Clinical Trial Results Database. Diabetes: vildagliptin. Study number LAF237A2205. www.novartisclinicaltrials.com/clinicaltrialrepository/ displayFile.do?trialResult=1475 (accessed 2006 Jul 31).
24. Novartis Clinical Trial Results Database. Diabetes: vildagliptin. Study number LAF237A2205E1. www.novartisclinicaltrials.com/clinicaltrialrepository/ displayFile.do?trialResult = 1891 (accessed 2006 Jul 31).
25. Fonseca V, Dejager S, Albrecht D, Shirt L, Schweizer A. Vildagliptin as add-on to insulin in patients with type 2 diabetes (poster). Presented at: American Diabetes Association 66th Annual Scientific Sessions, Washington, DC, June 11, 2006.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
27. Ahren B, Pacini G, Foley J, Schweizer A. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40.
28. Barilla D, He Y, Balez S, Bullock J, Ho Y, Gutierrez M, et al. No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide (poster). Presented at: American Diabetes Association 64th Annual Scientific Sessions, Orlando, FL, June 4-8, 2004.
29. Serra DB, He YL, Wang Y, et al. Combination of the DPP-4 inhibitor vildagliptin (LAF237) with pioglitazone is safe and well tolerated with no pharmacokinetic interaction (poster). Presented at: American Diabetes Association 65th Annual Scientific Sessions, San Diego, CA, June 10-14, 2005.